Genes preferentially expressed in embryo stomach are predominantly expressed in gastric cancer.
about
Molecules that target nucleophosmin for cancer treatment: an updateLAS1L interacts with the mammalian Rix1 complex to regulate ribosome biogenesisDevelopmental expression of the neurotensin gene in the rat liverGLTSCR2 is an upstream negative regulator of nucleophosmin in cervical cancer.NPM1 silencing reduces tumour growth and MAPK signalling in prostate cancer cells.Structure and functions of profilinsNucleophosmin suppresses oncogene-induced apoptosis and senescence and enhances oncogenic cooperation in cells with genomic instability.Computer-assisted stereological analysis of gastric volume during the human embryonic period.S137 phosphorylation of profilin 1 is an important signaling event in breast cancer progression.Prognostic significance of the co-expression of nucleophosmin and trefoil factor 3 in postoperative gastric cancer patientsNucleophosmin (NPM1) mutations in adult and childhood acute myeloid leukaemia: towards definition of a new leukaemia entity.Knockdown of NPM1 by RNA interference inhibits cells proliferation and induces apoptosis in leukemic cell line.Estrogen mediated expression of nucleophosmin 1 in human endometrial carcinoma clinical stages through estrogen receptor-α signaling.Silencing profilin-1 inhibits gastric cancer progression via integrin β1/focal adhesion kinase pathway modulationp16INK4A and p14ARF tumor suppressor pathways are deregulated in malignant rhabdoid tumors.An extensive tumor array analysis supports tumor suppressive role for nucleophosmin in breast cancerNucleophosmin interacts with FOXM1 and modulates the level and localization of FOXM1 in human cancer cells.Changes in the in vitro activity of platinum drugs when administered in two aliquots.Regulation of subcellular distribution and oncogenic potential of nucleophosmin by plakoglobin.Increased expression of nucleophosmin/B23 in hepatocellular carcinoma and correlation with clinicopathological parameters.TAT-mediated intracellular delivery of NPM-derived peptide induces apoptosis in leukemic cells and suppresses leukemogenesis in mice.HEXIM1, a New Player in the p53 PathwayNucleophosmin blocks mitochondrial localization of p53 and apoptosis.Deregulated expression of Nucleophosmin 1 in gastric cancer and its clinicopathological implications.Intrinsically disordered regions of nucleophosmin/B23 regulate its RNA binding activity through their inter- and intra-molecular association.Nucleophosmin/B23 is a negative regulator of estrogen receptor α expression via AP2γ in endometrial cancer cells.Implication of NPM1 phosphorylation and preclinical evaluation of the nucleoprotein antagonist N6L in prostate cancer.NPM1 histone chaperone is upregulated in glioblastoma to promote cell survival and maintain nucleolar shape.Nucleophosmin Interacts with PIN2/TERF1-interacting Telomerase Inhibitor 1 (PinX1) and Attenuates the PinX1 Inhibition on Telomerase Activity.Downregulation of NPM expression by Her-2 reduces resistance of gastric cancer to oxaliplatin.Chromosomal losses are associated with hypomethylation of the gene-control regions in the stomach with a low number of active genes.Analysis of NPM1 splice variants reveals differential expression patterns of prognostic value in acute myeloid leukemia.Analysis of the oligomeric states of nucleophosmin using size exclusion chromatography.
P2860
Q26750653-C250D28C-B611-4920-A424-966A8C133F71Q28255964-46E6AC5C-5C22-40F9-8C31-1AC0A2D62F88Q28580701-3926C2C8-4EB7-4871-AEF7-3A83B48AC036Q30032659-DF7BE179-2E77-4B52-BA3F-E7839F41CD2BQ33567915-5D3A35A1-56DF-45D0-9952-8C6F7ACCD2C1Q33659236-7A28E5BA-3F30-4559-ACC0-77D02A72502AQ33773430-27C40EA1-3A1F-4F44-80D1-C5D76E8D7D75Q33881821-DC7C9FA6-64BA-402E-893C-083D4A6DDDEEQ33989435-AEBEF66B-6A6D-44F1-9C47-16E3C1175F62Q34265710-1010E753-3FA1-4124-87F3-A086A566B3E6Q34755985-B5360197-7C55-4866-86E8-1EEC8D6C2C53Q34893776-5CC2B4A7-8AF3-4EE1-AB6C-79AF22F21F35Q35056262-D34F84A0-2007-4EB9-B264-BB11B29A5A55Q35128150-9AC956AD-A426-41EC-9283-63A84D281601Q35133362-4E07C9EA-2BAC-4104-8A55-A6C2FDF01CEDQ35168068-2BB279D4-D852-42F2-A295-DDD891C73DC0Q35842155-8371F5E4-8B33-43C1-BBDF-85695A8BBD6FQ36114723-3B4CC251-3D54-4A72-86B4-AF890F94CB5AQ36143099-63FA7172-2387-4A17-95BB-84053C15308FQ36609847-BD86358C-D15C-4F4C-94B5-26B260A28E1DQ36868764-18FCEA1E-94E3-41BF-A69D-FB705F18CC06Q37226490-4371B34E-6372-4B16-AEE1-BA0DFAB77946Q37269134-1E4BC46A-0961-4505-854B-1C43C391B356Q37485790-092897ED-6E4F-4F15-85F1-EEC7ADE47CC7Q37518568-B4541C59-A340-4C53-84EF-7A35415D126CQ37644981-50A942DD-86A7-4FED-8024-3C5DC93079A2Q37688379-A0FBEBAB-BAF9-4C57-9E30-BCC1E980110AQ38820099-17417E1F-1FFE-4282-A424-FA29DECD55BEQ38932205-8DD91511-B38A-41DD-9AC2-D4FA52584236Q42290643-1B463CF1-0E69-4EC2-BFC7-D9511D801A14Q43214665-B6852B36-9D09-4254-A39F-2190DFE45A5CQ47137221-EBF3BFFD-BD89-44AE-BE2E-DCA75BDFC481Q55006860-6DF7DC1C-3F34-4656-A573-F36393CFD494
P2860
Genes preferentially expressed in embryo stomach are predominantly expressed in gastric cancer.
description
1992 nî lūn-bûn
@nan
1992 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
1992 թվականի հունիսին հրատարակված գիտական հոդված
@hy
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
name
Genes preferentially expressed ...... y expressed in gastric cancer.
@ast
Genes preferentially expressed ...... y expressed in gastric cancer.
@en
type
label
Genes preferentially expressed ...... y expressed in gastric cancer.
@ast
Genes preferentially expressed ...... y expressed in gastric cancer.
@en
prefLabel
Genes preferentially expressed ...... y expressed in gastric cancer.
@ast
Genes preferentially expressed ...... y expressed in gastric cancer.
@en
P2093
P1433
P1476
Genes preferentially expressed ...... y expressed in gastric cancer.
@en
P2093
P304
P407
P577
1992-06-01T00:00:00Z